Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zanzalintinib · XL-092

Small molecule · Inhibitor of hepatocyte growth factor receptor (c-Met) (MET), vascular endothelial growth factor receptor 2 (VEGFR2) (KDR) and AXL receptor tyrosine kinase (AXL) · developed by Exelixis

Phase 3 Most advanced trial
EXEL Developer
3 Registered trials

What is Zanzalintinib?

Zanzalintinib is an orally bioavailable inhibitor of the receptor tyrosine kinases c-Met, VEGFR2, AXL and MER, binding these receptors and blocking their kinase activity. It is being studied in renal cell carcinoma and other advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XL-092
Drug type
Small molecule
Targets
hepatocyte growth factor receptor (c-Met) (MET), vascular endothelial growth factor receptor 2 (VEGFR2) (KDR), AXL receptor tyrosine kinase (AXL), MER proto-oncogene tyrosine kinase (MER) (MERTK)
Mechanism
Inhibitor of hepatocyte growth factor receptor (c-Met) (MET), vascular endothelial growth factor receptor 2 (VEGFR2) (KDR) and AXL receptor tyrosine kinase (AXL)
Pathways
c-Met/VEGFR2/AXL/MER signal transduction, angiogenesis, tumor cell proliferation and migration
Therapy area
Oncology
Developer
Exelixis (EXEL)
Also in trials of
BMY, MRK, RCUS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
KC2JC2ZA04

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06943755 Phase 2/3 Pancreatic Neuroendocrine Tumor (pNET) Recruiting EXEL
NCT05678673 Phase 3 Non-Clear Cell Renal Cell Carcinoma Active not recruiting EXEL
NCT06191796 Phase 1 Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors Terminated RCUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Clear Cell Renal Cell CarcinomaRenal Cell Carcinoma

Other drugs acting on MET / KDR / AXL / MERTK

More from Exelixis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EXEL page.

Follow EXEL, the company behind Zanzalintinib

See EXEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EXEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.